RenovoRx, Inc.

NASDAQ:RNXT

Biotechnology

Healthcare
$1.12 -0.86%

-$0.01 today

Market cap
$54.04M
Beta
0.99
P/E (TTM)
-3.4
EPS (TTM)
-$0.32
52W Low $0.70High $1.45

Volume 0.84M

Average 0.29M

RNXT Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

RenovoRx, Inc.NASDAQ: RNXT

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 38.03M shares rose 21.1% year over year, behind the +42.8% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 7.6% from the prior quarter. Over 3 fiscal years it compounded at +25.0% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +21.1% toward the trailing-twelve-month pace of +42.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
38.03M+7.6% QoQ
Last fiscal yearDec 2025
35.33M+49.7% YoY
LTMMar 2026
36.65M+42.8% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+21.1%——
1 year+49.7%——
3-year CAGR+25.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
35.33M USD
Year-over-year change
+49.7%
4-year CAGR
+18.6%

Weighted Avg Shares vs competitors

How RNXT compares with its peers on the latest reported figures

  • RNXT's LTM Mar 2026 weighted avg shares of 36.65M shares is the highest of the 6 companies compared; the peer median is 22.96M shares.
  • Its year-over-year change of +42.8% is the 3rd highest of 6, against a peer median of +27.8%.
  • Over three fiscal years its annual growth of +25.0% compares with a peer median of +36.0%.
RNXT Competitors Peer median
Weighted Avg Shares for RNXT and competitors
Company Period LTM YoY 3-year CAGR
RNXTRenovoRx, Inc.LTM Mar 202636.65M +42.8%+25.0%
MAIAMAIA Biotechnology, Inc.LTM Mar 202631.93M +27.8%+51.3%
CELUCelularity Inc.LTM Dec 202524.87M +13.6%+22.3%
ANVSAnnovis Bio, Inc.LTM Mar 202622.96M +82.7%+36.0%
PYPDPolyPid Ltd.LTM Mar 202618.85M +145.8%+132.8%
LTRNLantern Pharma Inc.LTM Mar 202610.94M +1.6%+0.1%
Peer median (excluding RNXT) 22.96M+27.8%+36.0%

Competitors are the stored peer set for RNXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00043K1.12M
Cost of Revenue0000327K
Gross Profit00043K796K
Gross Margin———100.0%70.9%
Research & Development3.04M4.3M5.67M6.03M6.27M
Selling, General & Admin2.63M5.65M5.73M4.99M7.04M
Operating Expenses5.67M9.95M11.4M11.01M13.31M
Depreciation & Amortization9K6K6K02K
EBITDA(5.48M)(9.83M)(10.12M)(8.81M)(11.17M)
EBITDA Margin———-20497.7%-994.3%
Operating Income(5.67M)(9.95M)(11.4M)(10.97M)(12.51M)
Operating Margin———-25511.6%-1114.0%
Interest Income70K57K0384K427K
Interest Expense904K57K108K00
Other Income / Expenses(653K)61K1.16M2.16M1.34M
Income Before Tax(6.32M)(9.89M)(10.23M)(8.81M)(11.17M)
Pre-Tax Margin———-20497.7%-994.5%
Income Tax Expense00000
Net Income(6.32M)(9.89M)(10.23M)(8.81M)(11.17M)
Net Margin———-20497.7%-994.5%
EPS (Basic)(0.40)(0.54)(0.50)(0.37)(0.32)
EPS (Diluted)(0.40)(0.54)(0.50)(0.37)(0.32)
Weighted Avg Shares17.87M18.1M20.58M23.61M35.33M
Weighted Avg Shares (Diluted)17.87M18.1M20.58M23.61M35.33M

RenovoRx, Inc.

NASDAQ:RNXT

Intrinsic Alpha fair value

Locked

Current Price

$1.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.